Titlebook: Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways; Yosef Yarden,Moshe Elkabets Book 2018

獨裁政府

Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways

大洪水

Resistance of Colorectal Tumors to Anti-EGFR Antibodies,on genetic lesions and share analogous signaling traits. Here we discuss how resistance to the EGFR blockade is attained in colorectal cancer and elaborate on alternative therapeutic strategies that are now under development to improve response and contrast relapse.

Narcissist

Book 2018, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate a

neologism

2196-5501 ase inhibitors and monoclonal antibodies, that specifically .This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth facto

竊喜

Resistance of Colorectal Tumors to Anti-EGFR Antibodies,s cetuximab or panitumumab (‘primary’ or ‘de novo’ resistance). Further, almost all patients who initially respond become resistant over the course of treatment (‘secondary’ or ‘a(chǎn)cquired’ resistance). Studies in cell lines, patient-derived tumorgrafts, and archival surgical specimens have identified

暫時過來

Resistance of Lung Cancer to Kinase Inhibitors Specific to EGFR or ALK,h factor receptor (EGFR) and the anaplastic lymphoma kinase (ALK) opened the way for development of relatively effective tyrosine kinase inhibitory (TKI) drugs, such as erlotinib and crizotinib, respectively. Unfortunately, resistance to these and other first-generation TKIs evolves in patients with

BRINK

Mechanisms of Action and Resistance of Trastuzumab in Breast Cancer, 2017. Breast cancer-related deaths have declined over the last two decades as a result of early detection and improved treatment, particularly targeted therapies, such as trastuzumab that targets human epidermal growth factor receptor 2 (HER2), which is frequently overexpressed in breast cancer. Ho

多樣

fiction

RAF, MEK and ERK Inhibitors as Anti-Cancer Drugs: Intrinsic and Acquired Resistance as a Major Thereractivation as well as oncogenic activating mutations in the different components of the cascade (mainly RAS, RAF and MEK) have inspired the development of several inhibitors targeting the different tiers of the cascade. As a result, clinically approved RAF and MEK inhibitors are used for targeted

Hypopnea

Mechanisms of Resistance to PI3K and AKT Inhibitors,te the binding and activation of PI3K, or as a consequence of activating alterations of the nodes of the signaling cascade, deregulated PI3K signaling can promote tumor growth and survival. This provided the rationale to develop inhibitors targeting virtually all the components of this pathway. Desp